Elsevier

The Lancet

Volume 360, Issue 9339, 5 October 2002, Pages 1089-1091
The Lancet

Rapid Review
The prospects for immunotherapy in smoking cessation

https://doi.org/10.1016/S0140-6736(02)11134-2Get rights and content

Section snippets

Animal models of a nicotine vaccine

Animal studies provide strong proof of principle for a nicotine vaccine (panel 1).12, 13, 14 These have shown that antibodies can be induced by attaching nicotine to a suitable antigenic protein,12, 15, 16 these antibodies have high affinity for nicotine, and they do not cross-react with its major metabolite, cotinine, or the neurotransmitter acetylcholine.14, 15

Nicotine antibodies modify the pharmacokinetics and the pharmacological effects of nicotine in rats. Passive immunisation reduced the

Relapse prevention

Active vaccination against nicotine could prevent relapse to regular smoking in abstinent smokers by markedly attenuating the rewarding effects of nicotine for weeks to months. Ex-smokers could be given a series of vaccinations against nicotine as part of a behavioural treatment programme with the aim of reducing the chance of a “slip” leading to daily smoking.14

A nicotine vaccine has three potential advantages over NRT and bupropion in relapse prevention (Panel 2). First, it would not require

Challenges in delivering a nicotine vaccine

The marketing of a nicotine vaccine faces a problem that is less likely to be faced by vaccines against other pyschoactive drugs like cocaine and phencyclidine for which no effective pharmacotherapy exists. Competing smoking-cessation products such as NRT and bupropion may affect the degree of commercial interest in funding the clinical development and registration of a nicotine vaccine. Partnerships may be needed between public-health services and pharmaceutical companies to facilitate trials

Conclusions

Animal studies suggest that a nicotine vaccine is a biologically plausible immunotherapeutic intervention that could be used to successfully assist cigarette smokers to cease smoking. It has several potential advantages over existing pharmacotherapeutic aids to smoking cessation: it sequesters nicotine in the bloodstream, thereby preventing it from entering the brain, it may have fewer side-effects than drugs that act on the CNS, and it is likely to have better compliance than oral drugs.

First page preview

First page preview
Click to open first page preview

References (24)

  • KO Fagerstrom

    Nicotine replacement therapies

  • Cited by (0)

    View full text